- Home
- MSEX vs PRAX Comparison
MSEX vs PRAX Comparison
Compare MSEX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSEX
- PRAX
- Stock Information
- Founded
- MSEX 1897
- PRAX 2015
- Country
- MSEX United States
- PRAX United States
- Employees
- MSEX N/A
- PRAX N/A
- Industry
- MSEX Water Supply
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- MSEX Utilities
- PRAX Health Care
- Exchange
- MSEX Nasdaq
- PRAX Nasdaq
- Market Cap
- MSEX 963.9M
- PRAX 952.1M
- IPO Year
- MSEX N/A
- PRAX 2020
- Fundamental
- Price
- MSEX $56.26
- PRAX $54.75
- Analyst Decision
- MSEX Buy
- PRAX Strong Buy
- Analyst Count
- MSEX 4
- PRAX 10
- Target Price
- MSEX $61.00
- PRAX $93.30
- AVG Volume (30 Days)
- MSEX 125.5K
- PRAX 431.3K
- Earning Date
- MSEX 10-30-2025
- PRAX 11-05-2025
- Dividend Yield
- MSEX 2.42%
- PRAX N/A
- EPS Growth
- MSEX 17.05
- PRAX N/A
- EPS
- MSEX 2.41
- PRAX N/A
- Revenue
- MSEX $195,831,000.00
- PRAX $7,765,000.00
- Revenue This Year
- MSEX $5.46
- PRAX N/A
- Revenue Next Year
- MSEX $8.74
- PRAX $20.00
- P/E Ratio
- MSEX $23.29
- PRAX N/A
- Revenue Growth
- MSEX 11.91
- PRAX 338.45
- 52 Week Low
- MSEX $48.18
- PRAX $26.70
- 52 Week High
- MSEX $70.73
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- MSEX 64.22
- PRAX 61.44
- Support Level
- MSEX $51.90
- PRAX $50.31
- Resistance Level
- MSEX $54.31
- PRAX $55.00
- Average True Range (ATR)
- MSEX 1.19
- PRAX 3.64
- MACD
- MSEX 0.29
- PRAX 0.51
- Stochastic Oscillator
- MSEX 94.64
- PRAX 91.62
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.